| Literature DB >> 31891788 |
Yasin Ahmadi1, Neda Mahmoudi2, Bahman Yousefi3, Ansar Karimian4.
Abstract
Statins, as the most common treatment for hyperlipidemia, exert effects beyond their lipid-lowering role which are known as pleiotropic effects. These effects are mainly due to the inhibition of isoprenoids synthesis and consequently blocking prenylation of proteins involved in the cellular signaling pathways regulating cell development, growth, and apoptosis. Statins target cholesterol synthesis in the liver as the major source of cholesterol in the body and so reduce whole-body cholesterol. The reduced level of cholesterol forces other organs to an adaptive homeostatic reaction to increase their cholesterol synthesis capacity, however, this only occurs when statins have unremarkable access to the extra-hepatic tissues. In order to reduce the adverse effects of statin on the skeletal muscle, most recent efforts have been towards formulating new statins with the highest level of hepatoselectivity rank and the least level of access to the extra-hepatic tissues; however, the inaccessibility of statins for the extra-hepatic tissues may induce several biological reactions. In this review, we aim to evaluate the effects of statins on the extra-hepatic tissues when statins have unremarkable access to these tissues.Entities:
Keywords: Atrophy; Cancer; Cell signaling; Cholesterol homeostasis; Mevalonate; Statin
Year: 2019 PMID: 31891788 DOI: 10.1016/j.phrs.2019.104621
Source DB: PubMed Journal: Pharmacol Res ISSN: 1043-6618 Impact factor: 7.658